Due to the explicit contribution of angiogenesis in the aggressiveness of GBM, bevacizumab, a monoclonal antibody targeting VEGF-A, has been approved by the FDA since 2004 for clinical use, and as a second-line treatment along with chemotherapy. This evidence concerns the gene VEGFA and glioblastoma.